IN THE CLAIMS:

Please amend the claims as follows:

- 20. (Amended) The immunogenic protein according to claim 17, comprising the amino acid sequence of SEQ ID NO:30, or part thereof having immunogenic properties.
- 23. (Twice Amended) An isolated nucleic acid comprising SEQ ID NO:29 or a nucleic acid that hybridizes, under stringent conditions, to a nucleotide sequence according to SEQ ID NO:29.
- 24. (Twice Amended) A method for identifying a cDNA clone which comprises an isolated nucleic acid sequence according to claim 21, the method comprising:
- (a) obtaining a radioactively or nonradioactively labeled oligonucleotide molecule having a sequence selected from the group consisting of SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; and SEQ ID NO:14, or parts thereof that hybridize to a sequence of the group under stringent conditions; and
- (b) screening a cDNA library prepared from Dictyocaulus viviparus using the labeled oligonucleptide molecule.

- 25. (Amended) A method for identifying a cDNA clone which comprises an isolated nucleic acid sequence according to claim 21, the method comprising:
- (a) obtaining a polymerase chain reaction primer having a sequence selected from the group consisting of SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; and SEQ ID NO:14, or parts thereof that hybridize to a sequence of the group under stringent conditions; and
- (b) screening a cDNA library or RNAs prepared from Dictyocaulus viviparus using the primer.

30. (Amended) A method for immunizing cattle against Dictyocaulus vivipanous comprising administering to a cattle in need thereof a vaccine according to claim 29.

REMARKS

Upon entry of the above amendment, claims 17-26 and 29-34 will be pending in the present application. Applicants have amended claims 20, 23-25 and 30. Applicants have amended claims 20 and 23-25 to clarify the subject matter claimed and correct syntax. Applicants have amended claim 30 to correct a typographical error. Applicants have not raised any issues of new matter.